FDA approves use of Leqembi Alzheimer\u0027s patients
On Thursday, the FDA gave full approval to the breakthrough drug Leqembi.CBS 2's Noel Brennan today's game-changing decision.The FDA addressed one of those concerns on Thursday. Medicare and Medicaid said it will now expand coverage of the drug. But with taking any drug, there are risks involved.
"It's a big day today, right? So today, we are all expecting approval, final approval from the FDA for Leqembi," Miravalle said. "Those individuals who received the medication had a benefit in terms of decreasing the progression of cognitive decline estimated at a 27% benefit," Miravalle said."One of the potential risks of the medication is brain swelling and in certain cases, rare, hemorrhages," Miravalle said."The estimated cost of the drug is thought to be about around $26,000 a year," said the doctor.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Read more »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Read more »
Alzheimer’s drug Leqembi granted full FDA approvalUPDATE: U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Read more »
Alzheimer’s drug Leqembi receives full FDA approvalThe Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Read more »
FDA Approves Promising New Alzheimer’s Drug LeqembiNot only is it the first Alzheimer’s antibody treatment to get full FDA approval, it’s also the first that will be broadly covered by Medicare.
Read more »
FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageDespite Medicare coverage, drug may remain out of reach for many patients, policy experts say
Read more »